Meitheal Pharmaceuticals Announces FDA Approval of High-Concentration Interchangeable YUSIMRY Biosimilar to Humira
Meitheal Pharmaceuticals, Inc., a Chicago-based fully integrated biopharmaceutical company focused on the development and commercialization of generic injectables, fertility products, biologics and branded medicines, announced that the U.S. Food and Drug Administration (FDA) has approved a high-concentration formulation (HCF) of YUSIMRY® (adalimumab-aqvh). The product is approved as an interchangeable biosimilar to Humira® (adalimumab), adding a high-concentration option to Meitheal’s existing YUSIMRY portfolio in the United States.
The approval represents another milestone for Meitheal’s expanding biologics business and gives the company FDA approval for both low- and high-concentration formulations of YUSIMRY. The product is intended for patients requiring treatment for chronic autoimmune and inflammatory conditions covered by the approved indications for adalimumab.
Emerge Bioscience Pte. Ltd. holds the approved Biologics License Application (BLA) for YUSIMRY. Under its licensing arrangement with Emerge, Meitheal serves as the product’s U.S. Regulatory Agent and holds exclusive U.S. commercialization rights.
The new approval further strengthens Meitheal’s position in the U.S. biosimilars market while supporting the company’s broader strategy of expanding access to high-quality and more affordable treatment options.
“With this approval, we now have FDA approval for both low and high-concentration formulations of YUSIMRY®, marking an important step in expanding treatment options for patients with certain chronic autoimmune diseases,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals. “By leveraging our development and commercialization expertise together with the manufacturing and supply chain capabilities of our partners, we will continue working to expand access to high-quality, affordable treatment options.”
High-Concentration YUSIMRY Expands Available Formulations
YUSIMRY is a biosimilar to Humira and has been approved by the FDA as interchangeable with Humira for all nine approved indications. The latest FDA decision adds the high-concentration formulation to the existing YUSIMRY offerings.
YUSIMRY is available in both low- and high-concentration formulations in an autoinjector, while the low-concentration formulation is also available as a prefilled syringe.
The availability of multiple formulations can be relevant to the administration and treatment experience of patients receiving long-term biologic therapy. Adalimumab is used across a broad range of chronic inflammatory and autoimmune diseases, making formulation availability an important component of treatment access.
The FDA’s interchangeable designation is also significant within the biosimilar market. Biosimilars are biologic products that are highly similar to an FDA-approved reference biological product, with no clinically meaningful differences in terms of safety, purity and potency. An interchangeable biosimilar meets additional FDA requirements related to interchangeability and may, subject to applicable state pharmacy laws, be substituted for the reference product at the pharmacy level.
For YUSIMRY, the interchangeable designation applies to Humira for all nine approved indications, according to Meitheal.
The addition of a high-concentration formulation gives the company another product option as it works to expand its presence in biologics and support broader patient access.
Meitheal Builds Momentum in Biologics
The YUSIMRY approval comes shortly after another important regulatory milestone for Meitheal.
In July 2026, the FDA approved Garzulys™ (insulin aspart-fsan) injection, adding another product to the company’s growing biologics business. Together with the approval of the high-concentration YUSIMRY formulation, the two milestones demonstrate the continued expansion of Meitheal’s portfolio across biologic and related therapeutic categories.
Meitheal has been investing in the infrastructure and capabilities needed to support its long-term development and commercialization strategy. The company is backed by its parent organization, Hong Kong King-Friend Industrial Co., Ltd. (HKF), which has supported more than $500 million in capital and research and development investments.
These investments include approximately $30 million in a monoclonal antibody drug substance facility, reflecting a broader focus on building capabilities related to biologics manufacturing and development.
For Meitheal, the expansion of its biologics portfolio is part of a wider strategy that encompasses generic injectables, fertility products, biologics and branded therapies. The company says its development and commercialization capabilities, combined with the manufacturing and supply chain resources of its partners, are intended to support the introduction of additional affordable medicines.
HKF Highlights Commitment to Affordable Biologic Medicines
HKF President Eric Tang highlighted the significance of the recent regulatory achievements involving both Garzulys and YUSIMRY.
“We are thrilled to celebrate both the FDA approval of Garzulys™ and the approval of the high-concentration formulation of YUSIMRY®,” Tang said. “Together, these achievements reinforce our commitment to increasing access to affordable biologic medicines. We look forward to continuing our strategic partnership with Meitheal and investing in solutions that help improve patient access and outcomes.”
The comments reflect the role of investment in supporting Meitheal’s expansion across biologics. Development and commercialization of biological medicines require specialized manufacturing capabilities, regulatory expertise and supply-chain infrastructure. Investments in these areas can support companies seeking to broaden their product portfolios and increase availability of biologic therapies.
The $30 million investment in a monoclonal antibody drug substance facility is one component of HKF’s broader investment in Meitheal’s operations and research and development activities.
Adalimumab Remains an Important Treatment Across Chronic Diseases
Adalimumab is a widely used biologic therapy that has become an important treatment option across multiple chronic inflammatory and autoimmune diseases.
Humira, the reference product for YUSIMRY, established adalimumab as a major biologic therapy for patients with a range of inflammatory conditions. Biosimilars such as YUSIMRY are designed to provide highly similar therapeutic options while potentially supporting competition and affordability within the biologic medicines market.
YUSIMRY’s approval as interchangeable with Humira across all nine approved indications provides Meitheal with a broad commercial platform. The addition of the high-concentration formulation further expands the company’s ability to offer different product configurations.
The development of high-concentration biologic formulations has also become an important area within the pharmaceutical industry. Concentration can influence injection volume and formulation characteristics, which may be relevant for patients receiving injectable medicines over extended periods. The latest YUSIMRY approval therefore adds another formulation option within Meitheal’s U.S. commercial portfolio.
Collaboration Supports U.S. Commercialization Strategy
Under its agreement with Emerge Bioscience, Meitheal holds exclusive U.S. commercialization rights for YUSIMRY and serves as the product’s U.S. Regulatory Agent.
This arrangement allows the companies to combine different areas of expertise. Emerge holds the approved BLA, while Meitheal is responsible for regulatory representation and commercial activities in the United States.
Such partnerships are increasingly important in the biosimilar industry, where successful commercialization requires more than regulatory approval. Companies must also establish manufacturing and supply-chain capabilities, maintain product availability and navigate the complex U.S. healthcare market.
Meitheal says its collaboration with Emerge, combined with the manufacturing and supply chain capabilities of its partners, will support continued efforts to expand access to biologic medicines.
The company’s latest approval also demonstrates the importance of maintaining a portfolio that includes different formulations and delivery options. With YUSIMRY now approved in both low- and high-concentration forms, Meitheal can offer a broader range of options within its adalimumab franchise.
Broader Implications for Biosimilar Access
The expansion of the YUSIMRY portfolio comes at a time when biosimilars continue to play an increasingly important role in the U.S. biologics market. As more biosimilar products become available, competition can provide additional treatment options for healthcare providers and patients while potentially contributing to greater affordability.
Interchangeable biosimilars are an important part of this landscape because of the regulatory pathway established by the FDA. The designation provides an additional level of regulatory recognition beyond biosimilarity and can facilitate substitution under applicable state laws.
For patients living with chronic autoimmune and inflammatory diseases, access to biologic medicines can be an important part of long-term disease management. Expanding the number of available products and formulations can contribute to a broader treatment landscape.
Meitheal’s latest FDA approval therefore extends beyond the addition of another formulation. It represents a continuation of the company’s effort to expand its biologics portfolio and establish a larger presence in the U.S. market.
Continued Investment in Meitheal’s Biologics Business
The approval of high-concentration YUSIMRY follows the FDA approval of Garzulys in July and underscores the pace of Meitheal’s recent biologics expansion.
With support from HKF and more than $500 million in capital and research and development investments, Meitheal is building capabilities intended to support the development and commercialization of additional therapies. The investment in a monoclonal antibody drug substance facility further demonstrates the company’s focus on strengthening its biologics infrastructure.
For Meitheal, these investments are designed to complement its existing expertise in generic injectables, fertility products, biologics and branded products.
The company now has FDA approval for both low- and high-concentration YUSIMRY formulations, while YUSIMRY remains approved as an interchangeable biosimilar to Humira for all nine approved indications.
As Meitheal continues to expand its biologics portfolio, the company says its focus will remain on leveraging development and commercialization expertise alongside manufacturing and supply-chain capabilities to increase access to high-quality, affordable treatment options.
The latest FDA decision provides another milestone in that strategy and strengthens Meitheal’s position in the U.S. biosimilar market while adding a high-concentration formulation to its YUSIMRY offering.
ABOUT YUSIMRY®
YUSIMRY® (adalimumab-aqvh), a biosimilar to Humira® (adalimumab), is a tumor necrosis factor (“TNF”) blocker indicated to reduce the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. Please see additional context for these indications and Important Safety Information below.